1 Min Read
Oct 13 (Reuters) - Aerie Pharmaceuticals Inc
* Aerie Pharmaceuticals Inc - FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.